

television providers in Columbus. TCI and TeleCable are the two largest cable television providers in the Columbus area in terms of the number of subscribers and the number of homes passed.

the agreement containing consent order would, if finally issued by the Commission, settle charges alleged in the Commission's complaint that TCI's acquisition of TeleCable would substantially lessen competition in the distribution of multichannel video programming by cable television in the Columbus, Georgia, area, in violation of Section 7 of the Clayton Act. The nature of such competition to be preserved is actual competition to serve existing homes, hotels, and apartment complexes. The order will also preserve competition for providing cable service to new housing developments and other presently cabled portions of the Columbus area. The Commission's complaint further alleges that TCI's merger agreement with TeleCable violates Section 5 of the Federal Trade Commission Act.

The order accepted for public comment would require TCI to divest a cable television system in the Columbus, Georgia, area. If TCI fails to divest a system within one year, the order allows the Commission to appoint a trustee to sell a cable system. A hold separate agreement executed in conjunction with the consent agreement requires TCI, until completion of the divestiture (or as otherwise specified), to maintain TeleCable's Columbus cable system separate from TCI's other operations. For ten (10) years from the date the order becomes final, the order would also prohibit TCI, without obtaining prior Commission approval, from acquiring any cable television system in the Columbus, Georgia, area.

The purpose of this analysis is to invite public comment concerning the consent order. This analysis is not intended to constitute an official interpretation of the agreement and order or to modify their terms in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 95-4280 Filed 2-21-95; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Acrylonitrile Study Advisory Panel, National Cancer Institute, National Institutes of Health, on Friday March 24, 1995. The meeting will be held in Conference Room H, Executive Plaza North, 6130 Executive Boulevard, Rockville, Maryland 20892.

This meeting will be open to the public from 10 am to 5 pm for discussion and review of study progress. Attendance by the public will be limited to space available.

Ms. Carole A. Frank, Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members, upon request.

Dr. Aaron Blair, Executive Secretary, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 418, 6130 Executive Boulevard, Rockville, Maryland 20892 (301/496-9093) will furnish substantive program information.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other special accommodations, should contact Dr. Aaron Blair, (301) 496-9093, in advance of the meeting.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-4244 Filed 2-21-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Health

National Cancer Institute; Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Cancer Institute (NCI) advisory committee meetings.

These meetings will be open to the public as indicated below with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Ms. Carole Frank, NCI Committee Management Officer, National Institutes of Health, Executive Plaza North, Room 630E, 6130 Executive Boulevard MSC 7405, Bethesda, Maryland 20892-7405, (301) 496-5708, will provide summaries of the meetings and rosters of committee members upon request. Substantive program information may be obtained from the contacts listed below.

Committee Name: Developmental Therapeutics Contracts Review Committee.

Contact Person: Dr. C. Michael Kerwin, Scientific Review Administrator, DEA, NCI, NIH, Executive Plaza North, Room 601A, 6130 Executive Boulevard, Rockville, MD 20852-7405, Telephone: (301) 496-7421

Date of Meeting: March 3, 1995

Place of Meeting: Executive Plaza North, Conference Room J, 6130 Executive Boulevard, Rockville, MD 20852

Closed: 9 am to adjournment

Agenda: Review, discussion and evaluation of individual contract proposals.

Committee Name: Board of Scientific Counselors, Division of Cancer Biology, Diagnosis, and Centers

Contact person: Dr. Ihor J. Masnyk, Executive Secretary, NCI, NIH, Building 31A, Room 3A11, 9000 Rockville Pike, Bethesda, MD 20892-2440, Telephone: (301) 496-3251

Date of Meeting: March 6, 1995

Place of Meeting: Building 31C—Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Rockville, MD 20892

Open: 8:30 am to adjournment

Agenda: Discussion and review of the division budget and review of concepts for grants and contracts.

These meetings will be closed, as indicated, in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-4242 Filed 2-21-95; 8:45 am]

BILLING CODE 4140-01-M

National Institutes of Health

National Institute of Mental Health; Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings of the National Institute of Mental Health Initial Review Group:

Agenda/Purpose: To review and evaluate grant applications

Committee Name: Child Psychopathology and Treatment Review Committee

Date: March 1-3, 1995

Time: 9 a.m.

Place: Wyndham Bristol Hotel, 2430 Pennsylvania Avenue NW., Washington, DC 20037

Contact Person: Bernice R. Cherry, Grants Technical Assistant, Parklawn Building, Room 9C-18, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-1367

Committee Name: Mental Health AIDS and Immunology Review Committee—1

Date: March 2-3, 1995

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Contact Person: Regina M. Thomas, Grants Technical Assistant, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470

Committee Name: Epidemiology and Genetics Review Committee

Date: March 5-7, 1995

Time: 9 a.m.

Place: Embassy Suites at Chevy Chase, 4300 Military Road, NW., Washington, DC 20015

Contact Person: Bernice R. Cherry, Grants Technical Assistant, Parklawn Building, Room 9C-18, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-1367

Committee Name: Mental Health AIDS and Immunology Review Committee—2

Date: March 6-7, 1995

Time: 8:30 a.m.

Place: Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814

Contact Person: Rehana A. Chowdhury, Grants Technical Assistant, Parklawn

Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the intramural research review cycle.

(Catalog of Federal Domestic Assistance Program Numbers 93.126, Small Business Innovation Research; 93.176, ADAMHA Small Instrumentation Program Grants; 93.242, Mental Health Research Grants; 93.281, Mental Research Scientist Development Award and Research Scientists Development Award for Clinicians; 93.282, Mental Health Research Service Awards for Research Training; and 93.921, ADAMHA Science Education Partnership Award.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-4243 Filed 2-21-95; 8:45 am]

BILLING CODE 4140-01-M

Substance Abuse and Mental Health Services Administration

Fiscal Year (FY) 1995 Notices of Funding Availability

AGENCY: Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Correction notice.

SUMMARY: Public notice was given in the **Federal Register** on February 10, 1995, Volume 60, No. 28, pages 7980-7984, of the funding opportunities for grants and cooperative agreements from the Center for Substance Abuse Prevention (CSAP) during FY 1995. On page 7983, under the Eligible Applicants section of 4.1.3 Community Prevention Coalitions Demonstration Grant Program, a statement was included that "the applicant must be part of an existing community partnership and must be designated to act on behalf of the larger coalition of multiple partnerships proposed in the grant application."

The requirement that the applicant must be part of an existing partnership has been deleted, and the revised Eligible Applicants section now states

that "the applicant must be designated to act on behalf of the larger evolving coalition of multiple partnerships proposed in the grant application."

Public notice was also given in the **Federal Register** on: January 4, 1995, Volume 60, No. 2, pages 474-478; January 30, 1995, Volume 60, No. 19, pages 5688-5691; and February 10, 1995, Volume 60, No. 28, pages 7977-7984; of the availability of funds from the SAMHSA Centers—Center for Mental Health Services, Center for Substance Abuse Prevention, and Center for Substance Abuse Treatment—for grant and cooperative agreement activities during FY 1995.

These notices specified that competing grant and cooperative agreement applications should be submitted to the Division of Research Grants, NIH, Westwood Building-Room 240, 5333 Westbard Avenue, Bethesda, MD 20892.

The mailing address for the Division of Research Grants, NIH, is being changed. Effective April 21, 1995, all competing SAMHSA applications must be sent to: Division of Research Grants, National Institutes of Health, 6701 Rockledge Drive MSC-7710, Bethesda, MD 20892-7710.*

Dated: February 16, 1995.

Richard Kopanda,

Acting Executive Officer, SAMHSA.

[FR Doc. 95-4323 Filed 2-21-95; 8:45 am]

BILLING CODE 4162-20-P

Cooperative Agreement with the Pennsylvania Department of Health

AGENCY: Center For Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration (SAMHSA), HHS.

ACTION: Notice of a planned single source, cooperative agreement award to support further development and continuation of a model comprehensive substance abuse treatment demonstration program for the City of Philadelphia.

SUMMARY: The Center for Substance Abuse Treatment (CSAT), SAMHSA, is publishing this notice to provide information to the public regarding a planned single source competing continuation award to the Pennsylvania Department of Health for the further development and operation of a model substance abuse treatment demonstration program. The current "Target Cities" project period will be

* Applicants who wish to use express mail or courier service should change the zip code to 20817-7710.